Jianqiu Du

Jianqiu Du

Auto-generated profile, based on publicly available information

Jianqiu Du

The Wistar Institute

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2026 in Nature Immunology
Verified
Journal Article
Open access
PDF file
IRIgnacio Rodríguez Relaño
Ignacio Rodríguez Relaño
JDJianqiu Du
Jianqiu Du
ZLZi Jie Lin
Zi Jie Lin
MKMargaret Kerwin
Margaret Kerwin
MTMarta Tarquis-Medina
Marta Tarquis-Medina
AEAmelia Escolano
Amelia Escolano
Sequential immunization is a promising approach to elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 Envelope (Env). However, available protocols are inefficient and involve multiple immunizations over long periods of time. Here, we present WIN332, a new engineered Env immunogen that induces a new class of Asn332-glycan-independent antibodies to the conserved V3-glycan epitope of Env with low inhibitory activity indicative of a neutralization activity after a single bolus immunization in nonhuman primates. WIN332 binds to precursors of canonical human Asn332-glycan-dependent (type-I) V3-glycan bNAbs but also of a first-of-its-class Asn332-glycan-independent (type-II) V3-glycan bNAb. A single immunization elicits low inhibitory serum and monoclonal antibodies that are boosted and affinity matured with a heterologous immunogen. Electron microscopy polyclonal epitope mapping analysis of serum antibodies, antibody cloning and cryogenic electron microscopy analysis reveals that WIN332 elicits Asn332-glycan-independent antibodies with striking sequence and binding similarities with the most potent human type-I and type-II V3-glycan bNAbs. Thus, WIN332 is a promising vaccine candidate to streamline V3-glycan bNAb elicitation.

24 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJiayan Cui
Jiayan Cui
ZLZi Jie Lin
Zi Jie Lin
SGSukanya Ghosh
Sukanya Ghosh
JDJianqiu Du
Jianqiu Du
RSRoopak Sadeesh
Roopak Sadeesh
JPJesper Pallesen
Jesper Pallesen
The molecular mechanism of HIV-1 entry into host cells is governed by dynamic conformational changes to its envelope glycoprotein (Env), which are triggered by the engagement of the host receptor CD4 and coreceptors. Structural insights into these transitions have been advanced by cryo-electron tomography (cryo-ET), resolving Env structures in closed and multifarious open states within native membranes, and by cryo-electron microscopy (cryo-EM), which has provided atomic details of these states. In this study, we determine cryo-EM structures of soluble native-like Env in complex with antibody 3BC315, antibody b12, CD4, or a combination of 3BC315 and b12, capturing previously uncharacterized conformational states. Observing enhanced 3BC315 binding occupancy in the presence of b12, we investigate the cooperativity of these antibodies using mass photometry and neutralization assays. Integrating these states with the literature, we establish a classification framework for symmetric and asymmetric Env states, categorizing by their degree of openness and stepwise structural rearrangements. Our findings refine the mechanistic understanding of HIV-1 Env dynamics and provide a structural roadmap for targeting dynamic Env states to develop more potent vaccines and immunotherapies.

24 June 2026 in Research Square
Verified
Preprint
Open access
PDF file
JPJesper Pallesen
Jesper Pallesen
JDJianqiu Du
Jianqiu Du
YWYuanhan Wu
Yuanhan Wu
SGSukanya Ghosh
Sukanya Ghosh
KBKelly Bayruns
Kelly Bayruns
DWDavid Weiner
David Weiner
The ongoing evolution of SARS-CoV-2, particularly the emergence of Omicron subvariants, compromised the effectiveness of many therapeutic antibodies. In this study, we employed a structure-guided computational design strategy to systematically optimize the COV2-2196 antibody for improved neutralization of Omicron variants. Through iterative rounds of computational design and experimental validation, we identified key paratope mutations that restored and enhanced antibody binding and neutralization potency against resistant viral strains. Cryo-EM structural analysis revealed the molecular basis for these improvements, highlighting how targeted modifications can accommodate epitope changes introduced by viral evolution. Our approach demonstrates that effective antibody optimization can be achieved using accessible computational resources, providing a practical framework for rapid therapeutic development. These findings underscore the potential of structure-based design to address challenges posed by viral antigenic drift and support the development of broadly effective antibody therapeutics for emerging infectious diseases.

30 June 2026 in bioRxiv
Verified
Preprint
Open access
LYLinlin Yang
Linlin Yang
MHMichael J. Hogan
Michael J. Hogan
SCStephen Carro
Stephen Carro
EHEmma J. Hedgepeth
Emma J. Hedgepeth
JDJianqiu Du
Jianqiu Du
LELaurence C. Eisenlohr
Laurence C. Eisenlohr
CD4 + T cells coordinate immune responses to infections and cancers and initiate many autoimmune diseases, yet the intracellular pathways that generate the peptide antigens they recognize remain incompletely understood. Progress has been limited in part by the scarcity of reagents that directly detect defined peptide:MHC class II (pMHC-II) complexes. Here, we established an mRNA vaccine-based pipeline to generate and characterize T cell receptor (TCR)-like antibodies. One result was 1D6, a monoclonal antibody specific for NA25:A b , an influenza A/PR8 neuraminidase-derived epitope presented by MHC-II. 1D6 bound NA25:A b with high affinity and specificity. 1D6 recognizes NA25:A b through binding determinants partially distinct from those used by the cognate TCR. Using this reagent, we confirmed the proteasome dependence of NA25 presentation and showed that NA25:A b accumulates in intracellular MHC-II loading compartments without a major requirement for canonical macroautophagy, pointing to an unconventional mode of antigen presentation. These findings establish TCR-like antibodies as powerful tools for dissecting noncanonical MHC-II antigen processing pathways. One Sentence Summary: An mRNA immunization strategy generated a highly specific antibody to study how a noncanonical natural epitope from influenza virus is produced and loaded onto MHC-II.

19 August 2026 in Research Square
Verified
Preprint
Open access
PDF file
JPJesper Pallesen
Jesper Pallesen
JDJianqiu Du
Jianqiu Du
SGSamuel Garfinkle
Samuel Garfinkle
KBKelly Bayruns
Kelly Bayruns
WZWujuan Zhang
Wujuan Zhang
AGAaron Goldman
Aaron Goldman
Structural understanding of T cell receptor (TCR) complexes is fundamental to deciphering immune recognition and signaling, with clear clinical relevance to infectious disease, cancer, and autoimmunity. Here, we present cryo-EM structures of a full-length TCR/CD3 complex—engineered to respond to an influenza peptide—both in the absence and presence of peptide-loaded MHCI ligand. Our results show that ectodomain TCR engineering preserves overall complex assembly and that peptide engagement induces localized conformational changes without altering the global architecture. By integrating lipidomics and computational modeling, we identify novel lipid binding sites within the TCR/CD3 complex, suggesting further potential regulatory roles for membrane lipids in TCR function. Additionally, using molecular dynamics simulations in tandem with surface plasmon resonance, we predict and confirm determinants of TCR affinity against mutant peptides and MHC surface residues. These findings provide new insights into the molecular organization and flexibility of the TCR/CD3 complex, offering a platform for future studies and engineering of T cell signaling and immune modulation.